Načítá se...
Enhanced efficacy of histone deacetylase inhibitor combined with bromodomain inhibitor in glioblastoma
BACKGROUND: Glioblastoma (GBM) is the most common and most malignant primary brain cancer in adults. Despite multimodality treatment, the prognosis is still poor. Therefore, further work is urgently required to discover novel therapeutic strategies for GBM treatment. METHODS: The synergistic effects...
Uloženo v:
| Vydáno v: | J Exp Clin Cancer Res |
|---|---|
| Hlavní autoři: | , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6167847/ https://ncbi.nlm.nih.gov/pubmed/30285808 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-018-0916-y |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|